Esperion Therapeutics Files Federal Suit Against Sandoz Inc.

Esperion Therapeutics sued Sandoz Inc. in a patent dispute that landed on the federal docket as case 24-cv-06387. The case was reassigned by court order on April 20, 2026.

No judge is currently listed as the presiding officer, and the reassignment order is the last substantive entry on the docket.

The underlying dispute appears to be a pharmaceutical patent case — Esperion makes bempedoic acid (sold as Nexletol and Nexlizile), a cholesterol-lowering drug, and Sandoz is a generic manufacturer.

Cases of this type typically arise under the Hatch-Waxman Act, where a generic filer's Abbreviated New Drug Application triggers a 30-month stay and a patent infringement suit. The docket does not yet confirm that procedural posture, but the parties fit the pattern exactly.

The April 2026 reassignment order is thin. Courts reassign cases for several reasons — recusal, docket rebalancing, or a related-case designation that pulls the matter to a different judge. None of those reasons appear on the face of the order.

Until a judge is formally assigned and enters an initial scheduling order, the case has no active litigation calendar.

What is missing from the public record is notable. The filing date is not confirmed, the original judge is not identified, and the key patent claims at issue have not been specified in available docket entries. That gap limits any read on how far along the parties are in claim construction or discovery.

Esperion has litigated Nexletol patents before, so prior related cases in other districts may inform what claims are in play here.

Sandoz, as the generic challenger, carries the burden of proving invalidity or non-infringement. Esperion, as the brand, will defend the patents and likely seek to preserve the 30-month stay if one is running. The commercial stakes are real — bempedoic acid competes in a crowded cardiovascular market, and generic entry would cut Esperion's revenue sharply.